市场趋势
| 短期 | 中期 | ||
| 行业 | Insurance - Life (US) | 混合的 | 混合的 |
| Insurance - Life (全球的) | 混合的 | 看涨 | |
| 股票 | aTyr Pharma, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
-1.8
| 分析师共识 | NA |
| 内部交易活动 | -3.0 |
| 价格波动 | -4.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.0 |
| 平均 | -1.75 |
|
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis. |
|
| 部门 | Financial Services |
| 行业 | Insurance - Life |
| 投资方式 | Small Value |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| ACCEL GROWTH FUND IV L.P. | 15.05 | 15.05 | 0 | 0 |
| BOTHA ROELOF | 17.03 | 15.05 | 260,525 | 4,949,975 |
| COLIS PETER GEORGE | - | 15.05 | -7,061,391 | -97,800,890 |
| GV 2017 GP, L.L.C. | 15.05 | 15.05 | 3,770,156 | 56,740,848 |
| KUCHARSKI BRANDT WALTER | - | 15.05 | -65,665 | -187,041 |
| LANTZ ERIN N | - | 15.05 | -227,464 | -2,448,289 |
| MULLIN MARK W. | 15.05 | - | 5,263 | 79,208 |
| SC US (TTGP), LTD. | 15.05 | 15.05 | 0 | 0 |
| SHARMA VIPUL | - | 15.05 | -412,132 | -3,010,000 |
| WANG LINGKE | - | 15.05 | -6,556,043 | -92,487,021 |
| WHEELER WILLIAM J | 15.05 | - | 260,525 | 3,920,901 |
| 累积净数量 | -10,026,226 | |||
| 累积净值 ($) | -130,242,309 | |||
| 累积平均购买 ($) | 15.54 | |||
| 累积平均卖出 ($) | 15.05 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| GV 2017 GP, L.L.C. | 30 Jan 2026 | 获得 (+) | 5,615,464 | 15.05 | 84,512,733 | |
| GV 2017 GP, L.L.C. | 30 Jan 2026 | 卖 (-) | 1,845,308 | 15.05 | 27,771,885 | |
| WANG LINGKE | 职员 | 30 Jan 2026 | 处理 (-) | 3,943,281 | 15.05 | 59,346,379 |
| WANG LINGKE | 职员 | 30 Jan 2026 | 处理 (-) | 2,202,036 | 15.05 | 33,140,642 |
| LANTZ ERIN N | 职员 | 30 Jan 2026 | 卖 (-) | 162,677 | 15.05 | 2,448,289 |
| COLIS PETER GEORGE | 职员 | 30 Jan 2026 | 处理 (-) | 6,154,683 | 15.05 | 92,627,979 |
| COLIS PETER GEORGE | 职员 | 30 Jan 2026 | 处理 (-) | 343,715 | 15.05 | 5,172,911 |
| KUCHARSKI BRANDT WALTER | 职员 | 30 Jan 2026 | 卖 (-) | 12,428 | 15.05 | 187,041 |
| MULLIN MARK W. | 董事 | 30 Jan 2026 | 买 (+) | 5,263 | 15.05 | 79,208 |
| WHEELER WILLIAM J | 董事 | 30 Jan 2026 | 买 (+) | 260,525 | 15.05 | 3,920,901 |
| SHARMA VIPUL | 职员 | 30 Jan 2026 | 卖 (-) | 200,000 | 15.05 | 3,010,000 |
| BOTHA ROELOF | 董事 | 30 Jan 2026 | 获得 (+) | 12,000,124 | 15.05 | 180,601,866 |
| BOTHA ROELOF | 董事 | 30 Jan 2026 | 处理 (-) | 12,000,124 | 15.05 | 180,601,866 |
| SC US (TTGP), LTD. | 30 Jan 2026 | 获得 (+) | 12,000,124 | 15.05 | 180,601,866 | |
| SC US (TTGP), LTD. | 30 Jan 2026 | 处理 (-) | 12,000,124 | 15.05 | 180,601,866 | |
| ACCEL GROWTH FUND IV L.P. | 30 Jan 2026 | 获得 (+) | 6,780,975 | 15.05 | 102,053,674 | |
| ACCEL GROWTH FUND IV L.P. | 30 Jan 2026 | 处理 (-) | 6,780,975 | 15.05 | 102,053,674 | |
| ACCEL GROWTH FUND IV L.P. | 30 Jan 2026 | 获得 (+) | 362,911 | 15.05 | 5,461,811 | |
| ACCEL GROWTH FUND IV L.P. | 30 Jan 2026 | 处理 (-) | 362,911 | 15.05 | 5,461,811 | |
| WANG LINGKE | 职员 | 29 Jan 2026 | 处理 (-) | 410,726 | 0.00 | 0 |
| LANTZ ERIN N | 职员 | 29 Jan 2026 | 处理 (-) | 64,787 | 0.00 | 0 |
| COLIS PETER GEORGE | 职员 | 29 Jan 2026 | 处理 (-) | 562,993 | 0.00 | 0 |
| KUCHARSKI BRANDT WALTER | 职员 | 29 Jan 2026 | 处理 (-) | 53,237 | 0.00 | 0 |
| SHARMA VIPUL | 职员 | 29 Jan 2026 | 处理 (-) | 212,132 | 0.00 | 0 |
| BOTHA ROELOF | 董事 | 29 Jan 2026 | 买 (+) | 260,525 | 19.00 | 4,949,975 |
| LANTZ ERIN N | 职员 | 28 Jan 2026 | 执行期权 | 85,244 | - | - |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合